GERRESHEIMER AG overview

EQS-News: Gerresheimer AG / Key word(s): Quarterly / Interim Statement Gerresheimer: Bormioli Pharma boosts revenues and earnings 11.04.2025 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Gerresheimer: Bormioli Pharma boosts revenues and earnings Revenues +11.6%, Adjusted EBITDA +13.1% Organic development compared to pro forma figures Q1 2024: revenues -6.5%, adjusted EBITDA -9.3% Q1 significantly influenced by revenue shift in syringe business Guidance...

Organic growth: revenue +2.9%, adjusted EBITDA +4.1% Destocking in vial business partially offset by strong growth in medical devices Growth strategy execution: capacity expansions and higher revenue share from solutions for biologics Bormioli Pharma to boost revenues and adjusted EBITDA from 2025 with integration well underway DUESSELDORF, GERMANY / ACCESS Newswire / February 26, 2025 / Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and...

EQS-News: Gerresheimer AG / Key word(s): Annual Results Gerresheimer delivers solid results in the financial year 2024 despite market headwinds 26.02.2025 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Gerresheimer delivers solid results in the financial year 2024 despite market headwinds Organic growth: revenue +2.9%, adjusted EBITDA +4.1% Destocking in vial business partially offset by strong growth in medical devices Growth strategy execution: capacity...

EQS-Ad-hoc: Gerresheimer AG / Key word(s): Tender Offer Gerresheimer AG confirms discussions with private equity investors on potential takeover offer 07-Feb-2025 / 16:26 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Gerresheimer AG confirms discussions with private equity investors on potential takeover offer...

EQS-News: Gerresheimer AG / Key word(s): Miscellaneous/Regulatory Admission Gerresheimer: FDA grants Tentative Approval of SQ Innovation’s Lasix® ONYU* 16.12.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. Gerresheimer: FDA grants Tentative Approval of SQ Innovation’s Lasix ® ONYU * Innovative combination product of furosemide and on-body device Ready-to-market device designed, developed and manufactured by Gerresheimer Patented device...

EQS-News: Gerresheimer AG / Key word(s): Mergers & Acquisitions Gerresheimer successfully completes acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group 11.12.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. Gerresheimer successfully completes acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group Complementary product portfolio and broad footprint of production sites in Europe Strengthening the...

EQS-News: Gerresheimer AG / Key word(s): Expansion Gerresheimer builds new production capacities for glass syringes at Skopje site 02.12.2024 / 13:30 CET/CEST The issuer is solely responsible for the content of this announcement. Gerresheimer builds new production capacities for glass syringes at Skopje site Expansion of the site in the Republic of North Macedonia with a new production hall for glass syringes Total investment volume of over EUR 100 million Around 250 new jobs for skilled workers...

EQS-News: Gerresheimer AG / Key word(s): ESG Solar power for Gerresheimer site in Momignies, Belgium 14.10.2024 / 11:00 CET/CEST The issuer is solely responsible for the content of this announcement. Solar power for Gerresheimer site in Momignies, Belgium 2.3 MWp rooftop photovoltaic system on production building Gerresheimer increases share of green electricity in its energy supply Goal for 2030: 100% electricity from renewable sources Duesseldorf/Momignies, October 14, 2024. Gerresheimer, an...